000			01372 a2200385 4500
005			20250514180452.0
264		0	_c20040503
008			200405s 0 0 eng d
022			_a0887-6924
024	7		_a10.1038/sj.leu.2403311 _2doi
040			_aNLM _beng _cNLM
100	1		_aChand, M
245	0	0	_aImatinib mesylate associated with delayed hematopoietic recovery after concomitant chemotherapy. _h[electronic resource]
260			_bLeukemia _cApr 2004
300			_a886-7; author reply 887-8 p. _bdigital
500			_aPublication Type: Case Reports; Comment; Letter
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology
650	0	4	_aBenzamides
650	0	4	_aHematopoiesis _xdrug effects
650	0	4	_aHumans
650	0	4	_aImatinib Mesylate
650	0	4	_aLeukemia, Myeloid, Chronic-Phase _xdrug therapy
650	0	4	_aLymphoma, B-Cell _xdrug therapy
650	0	4	_aLymphoma, Follicular
650	0	4	_aMale
650	0	4	_aNeoplasms, Second Primary _xdrug therapy
650	0	4	_aPiperazines _xadverse effects
650	0	4	_aPyrimidines _xadverse effects
700	1		_aThakuri, M
700	1		_aKeung, Y-K
773	0		_tLeukemia _gvol. 18 _gno. 4 _gp. 886-7; author reply 887-8
856	4	0	_uhttps://doi.org/10.1038/sj.leu.2403311 _zAvailable from publisher's website
999			_c14684041 _d14684041